Terms: = Endocrine gland cancer AND DEK, D6S231E, 7913, ENSG00000124795, P35659
13 results:
1. PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-dek interaction.
Ray U; Thirusangu P; Jin L; Xiao Y; Pathoulas CL; Staub J; Erskine CL; Dredge K; Hammond E; Block MS; Kaufmann SH; Bakkum-Gamez JN; Shridhar V
Oncogene; 2023 Sep; 42(37):2725-2736. PubMed ID: 37550562
[TBL] [Abstract] [Full Text] [Related]
2. Opium use as an independent risk factor for pancreatic cancer: A case-control study.
Naghibzadeh-Tahami A; Marzban M; Yazdi-Feyzabadi V; Khazaei Z; Zahedi MJ; Moazed V; Haghdoost AA
Cancer Epidemiol; 2021 Dec; 75():102017. PubMed ID: 34626910
[TBL] [Abstract] [Full Text] [Related]
3. Long noncoding RNA SOX2OT maintains the stemness of pancreatic cancer cells by regulating dek via interacting with miR-200a/141.
Liu CS; Zhou Q; Zhang YD; Fu Y
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2368-2379. PubMed ID: 32196588
[TBL] [Abstract] [Full Text] [Related]
4. First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.
Bengtsen MB; Veres K; Nørgaard M
Br J Cancer; 2020 Feb; 122(3):445-451. PubMed ID: 31806879
[TBL] [Abstract] [Full Text] [Related]
5. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract] [Full Text] [Related]
6. The dek Oncoprotein Functions in Ovarian cancer Growth and Survival.
Hacker KE; Bolland DE; Tan L; Saha AK; Niknafs YS; Markovitz DM; McLean K
Neoplasia; 2018 Dec; 20(12):1209-1218. PubMed ID: 30412857
[TBL] [Abstract] [Full Text] [Related]
7. dek protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract] [Full Text] [Related]
8. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Schwetz V; Librizzi R; Trummer C; Theiler G; Stiegler C; Pieber TR; Obermayer-Pietsch B; Pilz S
Metab Brain Dis; 2017 Feb; 32(1):155-161. PubMed ID: 27525431
[TBL] [Abstract] [Full Text] [Related]
9. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological significance of dek overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract] [Full Text] [Related]
11. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
[TBL] [Abstract] [Full Text] [Related]
12. Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A.
Cecconi D; Donadelli M; Rinalducci S; Zolla L; Scupoli MT; Scarpa A; Palmieri M; Righetti PG
Proteomics; 2007 May; 7(10):1644-53. PubMed ID: 17443844
[TBL] [Abstract] [Full Text] [Related]
13. Follicular variant of papillary thyroid carcinoma: clinical-pathological characterization and long-term follow-up.
Hagag P; Hod N; Kummer E; Cohenpour M; Horne T; Weiss M
Cancer J; 2006; 12(4):275-82. PubMed ID: 16925971
[TBL] [Abstract] [Full Text] [Related]
